<![CDATA[Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups]]>

ConferenceNeutral

AI Analysis

Summary

Dr. Marcio Fagundes discussed disease control outcomes by risk group in 404 prostate cancer patients treated with intensity-modulated proton therapy (IMPT) at a cancer conference.

Clinical Trial Data

Patients

404

Importance:3/10

Sentiment:

0.00

prostate cancerintensity-modulated proton therapyIMPTdisease controllocalized prostate cancer

Related Companies

$INTS

Read the original article

Published by Cancer Network on October 2, 2026 8:00 PM

Read Original